| Year |
Citation |
Score |
| 2019 |
Lorimer IA. Aberrant Rac pathway signalling in glioblastoma. Small Gtpases. 1-15. PMID 31032735 DOI: 10.1080/21541248.2019.1612694 |
0.322 |
|
| 2019 |
Jacques FH, Nicholas G, Lorimer I, Sikatifoko V, Prévost J. Avelumab in newly diagnosed glioblastoma multiforme: The SEJ study. Journal of Clinical Oncology. 37. DOI: 10.1200/Jco.2019.37.15_Suppl.E13571 |
0.314 |
|
| 2019 |
Lorimer I, Lavictoire S, Jomaa D, Gont A, Jardine K. Csig-12. Prex1 Links Aberrant Pi 3-Kinase Pathway Signaling To Maintenance Of The Neural Stem Cell-Like Phenotype Of Glioblastoma Cells Neuro-Oncology. 21. DOI: 10.1093/Neuonc/Noz175.183 |
0.43 |
|
| 2018 |
Kumar R, Lorimer I. Csig-06. The Molecular Subtype Of Primary Glioblastoma Cells Correlates With Response To Therapeutic Agents That Induce Apoptosis Or Senescence Neuro-Oncology. 20. DOI: 10.1093/Neuonc/Noy148.172 |
0.351 |
|
| 2016 |
Gont A, Daneshmand M, Woulfe J, Lavictoire SJ, Lorimer IA. PREX1 integrates G protein-coupled receptor and phosphoinositide 3-kinase signaling to promote glioblastoma invasion. Oncotarget. PMID 28051998 DOI: 10.18632/Oncotarget.14348 |
0.456 |
|
| 2015 |
Restall IJ, Parolin DA, Daneshmand M, Hanson JE, Simard MA, Fitzpatrick ME, Kumar R, Lavictoire SJ, Lorimer IA. PKCι DEPLETION INITIATES MITOTIC SLIPPAGE-INDUCED SENESCENCE IN GLIOBLASTOMA. Cell Cycle (Georgetown, Tex.). 0. PMID 26208522 DOI: 10.1080/15384101.2015.1071744 |
0.715 |
|
| 2015 |
Jahani-Asl A, Yin H, Soleimani V, Chang N, Sincennes M, Luchman HA, Sidharth P, Scott A, Lorimer I, Perkins T, Ligon K, Weiss S, Rudnicki M, Bonni A. CSIG-06EGFRvIII REQUIRES OSMR AS A CO-RECEPTOR TO DRIVE GLIOBLASTOMA PATHOGENESIS Neuro-Oncology. 17: v67.2-v67. DOI: 10.1093/Neuonc/Nov210.06 |
0.377 |
|
| 2014 |
Gont A, Hanson JE, Lavictoire SJ, Daneshmand M, Nicholas G, Woulfe J, Kassam A, Da Silva VF, Lorimer IA. Inhibition of glioblastoma malignancy by Lgl1. Oncotarget. 5: 11541-51. PMID 25426552 DOI: 10.18632/Oncotarget.2580 |
0.469 |
|
| 2014 |
Karapetis CS, Jonker D, Daneshmand M, Hanson JE, O'Callaghan CJ, Marginean C, Zalcberg JR, Simes J, Moore MJ, Tebbutt NC, Price TJ, Shapiro JD, Pavlakis N, Gibbs P, Van Hazel GA, ... ... Lorimer IA, et al. PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from NCIC CTG/AGITG CO.17. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 744-53. PMID 24218517 DOI: 10.1158/1078-0432.Ccr-13-0606 |
0.309 |
|
| 2013 |
Goss GD, O'Callaghan C, Lorimer I, Tsao MS, Masters GA, Jett J, Edelman MJ, Lilenbaum R, Choy H, Khuri F, Pisters K, Gandara D, Kernstine K, Butts C, Noble J, et al. Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 3320-6. PMID 23980091 DOI: 10.1200/Jco.2013.51.1816 |
0.346 |
|
| 2013 |
Liwak U, Jordan LE, Von-Holt SD, Singh P, Hanson JE, Lorimer IA, Roncaroli F, Holcik M. Loss of PDCD4 contributes to enhanced chemoresistance in Glioblastoma multiforme through de-repression of Bcl-xL translation. Oncotarget. 4: 1365-72. PMID 23965755 |
0.304 |
|
| 2013 |
Gont A, Hanson JE, Lavictoire SJ, Parolin DA, Daneshmand M, Restall IJ, Soucie M, Nicholas G, Woulfe J, Kassam A, Da Silva VF, Lorimer IA. PTEN loss represses glioblastoma tumor initiating cell differentiation via inactivation of Lgl1. Oncotarget. 4: 1266-79. PMID 23907540 DOI: 10.18632/Oncotarget.1164 |
0.705 |
|
| 2012 |
Daneshmand M, Hanson JE, Nabavi M, Hilton JF, Vandermeer L, Kanji F, Dent SF, Clemons M, Lorimer IA. Detection of PIK3CA Mutations in Breast Cancer Bone Metastases. Isrn Oncology. 2012: 492578. PMID 22970388 DOI: 10.5402/2012/492578 |
0.31 |
|
| 2012 |
Hilton J, Weberpals J, Lorimer I, Amin S, Islam S, Pelletier L, Daneshmand M, Hanson J, Nabavi M, Parolin D, Mallick R, Verma S. BRCA1 protein levels and PIK3CA mutations as predictive biomarkers for response to neoadjuvant chemotherapy in locally advanced breast cancer: An exploratory analysis. Oncology Letters. 4: 141-145. PMID 22807977 DOI: 10.3892/Ol.2012.697 |
0.363 |
|
| 2012 |
Paget JA, Restall IJ, Daneshmand M, Mersereau JA, Simard MA, Parolin DA, Lavictoire SJ, Amin MS, Islam S, Lorimer IA. Repression of cancer cell senescence by PKCι. Oncogene. 31: 3584-96. PMID 22120720 DOI: 10.1038/onc.2011.524 |
0.72 |
|
| 2011 |
Hilton J, Weberpals J, Lorimer I, Amin S, Islam S, Daneshmand M, Hanson J, Mallick R, Kanji F, Verma S. Abstract C1: BRCA1 protein levels and PI3KA mutations as predictive biomarkers for response to neoadjuvant chemotherapy in locally advanced breast cancer: An exploratory analysis. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-C1 |
0.38 |
|
| 2010 |
Goss GD, Lorimer I, Tsao MS, O'Callaghan CJ, Ding K, Masters GA, Roberts P, Jett JR, Edelman MJ, Shepherd FA. A phase III randomized, double-blind, placebo-controlled trial of the epidermal growth factor receptor inhibitor gefitinb in completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): NCIC CTG BR.19. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: LBA7005. PMID 27937477 DOI: 10.1200/Jco.2010.28.18_Suppl.Lba7005 |
0.334 |
|
| 2010 |
Baldwin RM, Barrett GM, Parolin DA, Gillies JK, Paget JA, Lavictoire SJ, Gray DA, Lorimer IA. Coordination of glioblastoma cell motility by PKCι. Molecular Cancer. 9: 233. PMID 20815904 DOI: 10.1186/1476-4598-9-233 |
0.378 |
|
| 2010 |
Restall IJ, Lorimer IA. Induction of premature senescence by hsp90 inhibition in small cell lung cancer. Plos One. 5: e11076. PMID 20552022 DOI: 10.1371/journal.pone.0011076 |
0.712 |
|
| 2010 |
Hilton JF, Weberpals JI, Lorimer I, Nabavi M, Kanji F, Hopkins S, Robertson S, Daneshmand M, Verma S. Can tumor biomarkers predict response to neoadjuvant anthracycline/taxane chemotherapy in LABC? Journal of Clinical Oncology. 28: 633-633. DOI: 10.1200/Jco.2010.28.15_Suppl.633 |
0.313 |
|
| 2010 |
Paget J, Daneshmand M, Amin MS, Islam S, Lorimer I. Abstract 3171: Expression of PKC iota in breast cancer Cancer Research. 70: 3171-3171. DOI: 10.1158/1538-7445.Am10-3171 |
0.444 |
|
| 2008 |
Cemeus C, Zhao TT, Barrett GM, Lorimer IA, Dimitroulakos J. Lovastatin enhances gefitinib activity in glioblastoma cells irrespective of EGFRvIII and PTEN status. Journal of Neuro-Oncology. 90: 9-17. PMID 18566746 DOI: 10.1007/S11060-008-9627-0 |
0.348 |
|
| 2007 |
Agulnik M, Cohen EW, Cohen RB, Chen EX, Vokes EE, Hotte SJ, Winquist E, Laurie S, Hayes DN, Dancey JE, Brown S, Pond GR, Lorimer I, Daneshmand M, Ho J, et al. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 3978-84. PMID 17761983 DOI: 10.1200/Jco.2007.11.8612 |
0.322 |
|
| 2005 |
Tsao MS, Sakurada A, Lorimer I, Cutz JC, Kamel-Reid S, Squire J, Ding K, Frank R, Seymour L, Shepherd F. Molecular analysis of the epidermal growth factor receptor (EGFR) gene and protein expression in patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial BR.21. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 7007. PMID 27943794 DOI: 10.1200/Jco.2005.23.16_Suppl.7007 |
0.326 |
|
| 2005 |
Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, Lorimer I, Zhang T, Liu N, Daneshmand M, Marrano P, da Cunha Santos G, Lagarde A, Richardson F, Seymour L, et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. The New England Journal of Medicine. 353: 133-44. PMID 16014883 DOI: 10.1056/Nejmoa050736 |
0.355 |
|
| 2005 |
Mackenzie MJ, Hirte HW, Glenwood G, Jean M, Goel R, Major PP, Miller WH, Panasci L, Lorimer IA, Batist G, Matthews S, Douglas L, Seymour L. A phase II trial of ZD1839 (Iressa) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer. Investigational New Drugs. 23: 165-70. PMID 15744593 DOI: 10.1007/S10637-005-5862-9 |
0.334 |
|
| 2002 |
Lorimer IA, Parolin DA, Lavictoire SJ. Induction of apoptosis in glioblastoma cells by an atypical protein kinase C pseudosubstrate peptide. Anticancer Research. 22: 623-31. PMID 12014630 |
0.361 |
|
| 1995 |
Lorimer IA, Wikstrand CJ, Batra SK, Bigner DD, Pastan I. Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 1: 859-64. PMID 9816055 |
0.304 |
|
| 1994 |
Jain N, Brickenden A, Lorimer I, Ball EH, Sanwal BD. Interaction of procollagen I and other collagens with colligin Biochemical Journal. 304: 61-68. PMID 7998958 DOI: 10.1042/Bj3040061 |
0.65 |
|
| 1993 |
Clarke EP, Jain N, Brickenden A, Lorimer IA, Sanwal BD. Parallel regulation of procollagen I and colligin, a collagen-binding protein and a member of the serine protease inhibitor family. The Journal of Cell Biology. 121: 193-9. PMID 8458868 DOI: 10.1083/Jcb.121.1.193 |
0.565 |
|
| 1987 |
Lorimer IA, Mason ME, Sanwal BD. Levels of type I cAMP-dependent protein kinase regulatory subunit are regulated by changes in turnover rate during skeletal myogenesis Journal of Biological Chemistry. 262: 17200-17205. PMID 2445756 |
0.589 |
|
| Show low-probability matches. |
